Comparative Pharmacology
Head-to-head clinical analysis: CARBAMAZEPINE versus ESLICARBAZEPINE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBAMAZEPINE versus ESLICARBAZEPINE ACETATE.
CARBAMAZEPINE vs ESLICARBAZEPINE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbamazepine stabilizes the inactivated state of voltage-gated sodium channels, thereby reducing neuronal excitability and repetitive firing. It also potentiates GABAergic transmission and affects calcium and potassium channels.
Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes the inactive state of sodium channels, reducing high-frequency repetitive firing of neurons. It also modulates T-type calcium channels and enhances slow inactivation of sodium channels.
Initial 200 mg orally twice daily, increase by 200 mg/day every 7 days; usual maintenance 800-1200 mg/day in divided doses (max 1600 mg/day).
400 mg orally once daily, titrated to a maintenance dose of 800-1200 mg once daily.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateCarbamazepine + Digoxin
"The metabolism of Digoxin can be increased when combined with Carbamazepine."
Clinical Note
moderateCarbamazepine + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Carbamazepine."
Clinical Note
moderateCarbamazepine + Torasemide
"The metabolism of Torasemide can be increased when combined with Carbamazepine."
Clinical Note
moderateCarbamazepine + Clobetasol propionate
Initial: 25-65 hours (single dose), then 12-17 hours (chronic dosing due to autoinduction). Clinical context: autoinduction reduces half-life over 3-5 weeks; adjust dosing accordingly.
Terminal half-life of eslicarbazepine is 13-20 hours (mean ~14 hours), supporting once-daily dosing.
Renal: 72% (primarily as metabolites including carbamazepine-10,11-epoxide, with ~1-3% as unchanged drug); Fecal: 28% via biliary elimination.
Renal: ~90% (as glucuronide conjugates and unchanged drug; ~30% as eslicarbazepine acetate, ~60% as eslicarbazepine). Fecal: <1%. Biliary: negligible.
Category D/X
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Clobetasol propionate can be decreased when it is combined with Carbamazepine."